|
|
Blood, 15 July 2007, Vol. 110, No. 2, pp. 783-786.
Prepublished online as a Blood First Edition Paper on March 29, 2007; DOI 10.1182/blood-2006-10-054510.
Previous Article | Next Article 
Submitted October 27, 2006
Accepted March 19, 2007
Absence of donor T cell derived soluble TNF decreases graft-versus-host-disease without impairing graft-versus-tumor activity
Chiara Borsotti, Anna RK Franklin, Sydney X Lu, Theo D Kim, Odette Marsinay Smith, David Suh, Chris G King, Andrew Chow, Chen Liu, Onder Alpdogan, and Marcel RM van den Brink*
Departments of Medicine and Immunology, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
Department of Pathology, Immunology and Laboratory Medicine, University of Florida, College of Medicine, Gainesville, FL, United States
* Corresponding author; email: vandenbm{at}mskcc.org.
Tumor necrosis factor (TNF) plays an important role in graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) after allogeneic bone marrow transplantation (allo-BMT). TNF can be expressed in a membrane-bound form (memTNF) and as a soluble (solTNF) molecule after being cleaved by the TNF- converting enzyme (TACE). To study the contribution of donor T cell-derived memTNF versus solTNF in GVHD and GVT, we used mice containing a non-cleavable allele in place of endogenous TNF (memTNF / ) as donors in murine BMT models. Recipients of memTNF T cells developed significantly less GVHD than recipients of wild-type (wt) T cells. In contrast, GVT activity mediated by memTNF T cells remained intact, and alloreactive memTNF T cells showed no defects in proliferation, activation and cytotoxicity. These data suggest that suppressing the secretion of solTNF by donor T cells significantly decreases GVHD without impairing GVT activity.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. W. Kappel, G. L. Goldberg, C. G. King, D. Y. Suh, O. M. Smith, C. Ligh, A. M. Holland, J. Grubin, N. M. Mark, C. Liu, et al.
IL-17 contributes to CD4-mediated graft-versus-host disease
Blood,
January 22, 2009;
113(4):
945 - 952.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yi, D. Zhao, C.-L. Lin, C. Zhang, Y. Chen, I. Todorov, T. LeBon, F. Kandeel, S. Forman, and D. Zeng
Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease
Blood,
September 1, 2008;
112(5):
2101 - 2110.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Levine, S. Paczesny, S. Mineishi, T. Braun, S. W. Choi, R. J. Hutchinson, D. Jones, Y. Khaled, C. L. Kitko, D. Bickley, et al.
Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease
Blood,
February 15, 2008;
111(4):
2470 - 2475.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|